
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals Inc. has demonstrated a positive trajectory with its key product, etripamil, as evidenced by promising results from the Phase 2 ReVeRA study, which indicated significant improvements in symptom relief for patients, bolstered by positive patient-reported outcomes. The company has also secured FDA agreement for a streamlined Phase 3 program for the treatment of atrial fibrillation with rapid ventricular rate, suggesting a clear regulatory pathway ahead and potentially expediting commercial opportunities. Additionally, with an increased estimated market share in paroxysmal supraventricular tachycardia and a 100% probability of success for its CARDAMYST initiative, Milestone appears well-positioned for a successful commercial launch that could generate considerable shareholder value in the near term.
Bears say
Milestone Pharmaceuticals faces a challenging financial outlook due to the underappreciation of its long-term revenue potential from etripamil, projected at nearly $2 billion worldwide, contingent on regulatory approval. Despite the significant reduction in heart rate observed in patients, the current phase of clinical trials may result in near-term revenue moderation, raising concerns about the company's financial stability. The reliance on successful outcomes in ongoing trials for AFib-RVR alongside the competitive landscape of cardiovascular medications adds to the uncertainty regarding the stock's performance.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares